

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER POR PATENTS PO Box (430 Alexandra, Virginia 22313-1450 www.ouplo.gov

	1	I		
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/723,908	11/26/2003	Peter Andersen	0459-0752P	5514
2592 7590 69/16/2009 BIRCH STEWART KOLASCH & BIRCH PO BOX 747			EXAMINER	
			SWARTZ, RODNEY P	
FALLS CHURCH, VA 22040-0747			ART UNIT	PAPER NUMBER
		1645		
			NOTIFICATION DATE	DELIVERY MODE
			09/16/2009	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com

Application No. Applicant(s) 10/723 908 ANDERSEN ET AL. Office Action Summary Examiner Art Unit Rodney P. Swartz, Ph.D. 1645 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 05 June 2009. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-12.14-18.27 and 46-50 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) 1-11.14-18.27 and 46-50 is/are allowed. Claim(s) _____ is/are rejected. 7) Claim(s) 12 is/are objected to. 8) Claim(s) _____ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s)

1) Notice of References Cited (PTO-892)

Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) information Disclosure Statement(s) (PTO/S6/08)
Paper No(s)/Mail Date _____

Interview Summary (PTO-413)
 Paper No(s)/Mail Date.

6) Other:

5) Notice of Informal Patent Application

Application/Control Number: 10/723,908 Page 2

Art Unit: 1645

DETAILED ACTION

Applicants' Response to Office Action, received 5 June 2009, is acknowledged. Claims 1,

2, 3, 5 and 17 have been amended. Claims 28-45 have been cancelled.

Applicants' Supplemental Response to Office Action, received 19 June 2009, is acknowledged. Claim 3 has been amended.

3. Claims 1-12, 14-18, 27 and 46-50 are pending and under consideration.

Rejections Withdrawn

- The rejection of claims 1-3 under 35 U.S.C. 112, second paragraph, as being indefinite for "and", is withdrawn in light of the amendment of the claims.
- The rejection of claims 1-3 under 35 U.S.C. 112, second paragraph, as being indefinite for "said polypeptide", is withdrawn in light of the amendment of the claims.
- 6. The rejection of claims 1, 2, 4-12, 14-18, 27 and 46-50 under 35 U.S.C. 112, second paragraph, as being indefinite for "comprises", is withdrawn in light of the amendment of the claims.
- 7. The rejection of claims 1-12, 14-18, 27 and 46-50 under 35 U.S.C. 112, second paragraph, as being indefinite for "immunologically equivalent" is withdrawn in light of applicants' arguments and statement that "immunologically equivalent" means that both polypeptide fragments must satisfy the same property selected from properties i-viii as listed on page 13. lines 1-3 of the specification.

Double Patenting

8. Claim 12 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 1.
When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim

Application/Control Number: 10/723,908

Art Unit: 1645

to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k).

Claim 12 recites: A substantially pure polypeptide according to claim 1 for use as a pharmaceutical.

The recital of "for use as a pharmaceutical" is merely an intended use and places no patentability to the claim. Thus, claim 12 is a substantial duplicate of claim 1.

Conclusion

- 9. Claim 12 is objected to.
- Applicant's amendment necessitated the new ground(s) of rejection presented in this
 Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a).
 Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

11. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rodney P. Swartz, Ph.D., Art Unit 1645, whose telephone number is (571) 272-0865. The examiner can normally be reached on Monday through Wednesday from 9:00 AM to 7:30 PM EST. Thursday is the examiner's work at home day.

Art Unit: 1645

If attempts to reach the Examiner by telephone are unsuccessful, please contact the Examiner's Supervisor, Robert B. Mondesi (571)272-0956.

The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Rodney P. Swartz, Ph.D./
Primary Examiner, Art Unit 1645
September 14, 2009